Antipsychotic medications for cocaine dependence

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Amato, Laura ^a   Minozzi, S ^b   Pani, P P ^b   Davoli, M ^b  

^a ASL RM/E   (Italy)

^b NONE

Author keywords

Antipsychotic agents *therapeutic use ; Benzodiazepines therapeutic use ; Cocaine related disorders *drug therapy ; Haloperidol therapeutic use ; Humans; Randomized controlled trials as topic; Risperidone therapeutic use

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; DROPERIDOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; TETRABENAZINE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE;

CLINICAL PRACTICE; CLINICAL TRIAL; COCAINE DEPENDENCE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG EXPOSURE; HUMAN; RANDOMIZATION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; WITHDRAWAL SYNDROME;

EID: 44949167775     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006306.pub2     Document Type: Review

References (72)

1. Berger 1996 {published data only} *Berger SP, Hall S. Mickallan JD, Reid MS, Crawford CA, Delucchi K, et al. Haloperidol antagonism of cue-elicited cocaine craving. Lancet 1996;347(9000):504-8.
2. Grabowski arm a 2004 {published data only} *Grabowski J, Rhoades H, Stotts A, Cowan K, Kopecky C, Dougherty A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004;29(7):969-81.
3. Grabowski arm b 2004 {published data only} Grabowski J, Rhoades H, Stotts A, Cowan K, Kopecky C, Dougherty A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004;29(7):969-81.
4. Kampman 2003 {published data only} *Kampman KM, Pettinati H, Lynch KG, Sparkman T, O'Brien CP. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug and Alcohol Dependence 2003;70(3):265-73.
5. Levin 1999 {published data only} *Levin FR, McDowell D, Evans SM, Brooks D, Spano C, Nunes EV. Pergolide mesylate for cocaine abuse: a controlled preliminary trial. The American Journal on Addiction 1999;8(2):120-7.
6. Reid 2005 {published data only} *Reid MS, Casadonte P, Baker S, Sanfilippo M, Braunstein D, Hitzemann R, et al. A placebo-controlled screening trial of olanzapine, valproate and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction 2005;100((Sup 1)):43-57.
7. Smelson 2004 {published data only} *Smelson DA, Williams J, Ziedonis D, Sussner BD, Losonczy MF, Engelhart C, et al. A double-blind placebo controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. Journal of Substance Abuse Treatment 2004;27(1):45-9.
8. Smelson 2006 {published data only} *Smelson DA, Ziedonis D, Williams J, Losonczy MF, Williams J, Steinberg ML, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence. Journal of Clinical Psychopharmacology 2006;26(1):9-12.
9. De La Garza 2005 De La Garza R, Newton TF. Risperidone diminishes cocaine-induced craving. Psychopharmacology 2005;178(2-3):347-50.
10. Evans 2001 Evans SM, Walsh SL, Levin FR, Foltin RW, Fischman MW, Bigelow GE. Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans. Drug and Alcohol Dependence 2001;64(3):271-83.
11. Farren 2000 Farren CK, Hameedi FA, Rosen MA, Woods S, Jatlow P, Kosten TR. Significant interaction between clozapine and cocaine in cocaine addicts. Drug and Alcohol Dependence 2000;59(2):153-63.
12. Gawin 1989 Gawin FH, Allen D, Humblestone B. Outpatient treatment of "crack" cocaine smoking with flupenthixol decanoate. Archives of General Psychiatry 1989;46(4):322-5.
13. Grabowski 2000 Grabowski J, Rhoades H, Silverman P, Schmitz JM, Stotts A, Creson D, et al. Risperidone for the treatment of cocaine dependence: randomized, double trial. Journal of Clinical Psychopharmacology 2000;20(3):305-10.
14. Landabaso 2003 Landabaso M, Iraurgi I, Jimenez JM, Hormaechea JA, Sanz J, Larrazabal A, et al. Olanzapina and cocaine consumption in methadone maintenance programs: new results [Olanzapina y consumo de cocaina en programas de mantenimiento con metadona: nuevos resultados]. Psiq Biol 2003;10(5):160-4.
15. Price 1997 Price LH, Pelton GH, McDougle CJ, Malison RT, Jatlow P, Carpenter L, et al. Effects of acute pretreatment with risperidone on responses to cocaine in cocaine addicts. Poster presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawai, USA. 1997.
16. Sayers 2005 Sayers SL, Campbell EC, Kondrich J, Mann SC, Cornish J, O'Brien C, et al. Cocaine abuse in schizophrenic patients with olanzapine versus haloperidol. The Journal of Nervous and Mental Diseases 2005;139(6):379-86.
17. Sherer 1988 Sherer MA, Kumor KM, Jaffe JH. Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Research 1988;27(2):117-25.
18. Smelson 2002 Smelson DA, Losonczy MF, Craig WD, Kaune M, Williams J, Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Canadian Journal of Psychiatry 2002;47(7):671-3.
19. Stone 1993 Stone AM, Greenstein RA, Gamble G, McLellan TA. Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication. Hospital and Community Psychiatry 1993;44(2):176-7.
20. Tsuang 2002 Tsuang J, Marder SR, Han A, Hsieh W. Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry 2002;63:1180-1.
21. Brown S A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence. Ongoing study November 2005.
22. Grabowski J Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals. Ongoing study June 2006.
23. Haney M Effects of Aripiprazole on Cocaine Craving and Self-Administration. Ongoing study April 2005.
24. Nejtek VA A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder Outpatients With Current Stimulant Dependence. Ongoing study October 2002.
25. Rush CR Preventing Cocaine Relapse: Developing Pharmacotherapies. Ongoing study January 2006.
26. Berk 1999 Berk M, Brooks S, Trandafir A. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double blind, randomized controlled trial. Int. Clin. Psychopharmacol 1999;14(3):177-80.
27. Chalmers 1993 Chalmers I. The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. Annals of the New York Academy of Sciences 1993;703:156-63; discussion 163-5.
28. Childress 1986 Childress AR, McLellan AT, O'Brien CP. Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both throught extinction. British Journal of Addiction 1986;81(5):655-60.
29. Craddok 1997 Craddok SG, Rounds-Bryant JL, Flinn PM, Hubbard RL. Characteristics and pre-treatment behaviours of clients entering drug abuse treatment: 1969 to 1993. American Journal of Drug and Alcohol Abuse 1997;23(1):43-59.
30. Dackis 2002 Dackis CA, O'Brien CP. Cocaine dependence: the challenge for pharmacotherapy. Current Opinion in Psychiatry 2002;15:261-8.
31. Davoli in press Davoli M, Pasqualini F, Belleudi V, Bargagli AM, Perucci CA. Changing pattern of drug abuse among patients entering treatment in Lazio, Italy, 1996-2003: transition from heroin to cocaine use. European Addiction Research.
32. Di Chiara 1988 Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988;85(14):5274-8.
33. Drevets 1999 Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Holt D, et al. PET Measures of Amphetamine-Induced Dopamine Release in Ventral versus Dorsal Striatum. Neuropsychopharmacology 1999;21(6):694-709.
34. Drevets 2001 Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, et al. Amphetamine-Induced Dopamine Release in Human Ventral Striatum Correlates with Euphoria. Biol. Psychiatry 2001;49(2):81- 96.
35. DSM IV R AAVV. Diagnostic and Statistical Manual of Mental Disorders. 4 edition. Washington DC: American Psychiatric Association, 1994.
36. EMCDDA 2006 The state of the drugs problem in the European Union and Norway. European Monitoring Centre for Drug and Drug Abuse; Luxemburg 2006.
37. Faggiano 2003 Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews 2003, Issue 3.
38. Filip 2005 Filip M, Frankowska M, Zaniewska M, Golda A, Przegalinski E. The serotonergic system and its role in cocaine addiction. Pharmacol Rep 2005;57(6):685-700.
39. Grabowski 1997 Grabowski J, Roache JD, Scmitz JM, Rhoades H, Creson D, Korszun A. Replacement medication for cocaine dependence. Journal of Clinical Psychopharmacology 1997;17(6):485-8.
40. Guy 1976 Guy W. Assessment Manual for Psychopharmacology. Vol. Publication ADM 76-338, Washington DC: US Department of Health Education and Welfare, 1976.
41. Hamilton 1959 Hamilton M. The assessment of anxiety states by rating. British Journal Med Psycol 1959;32(1):50-5.
42. Hamilton 1967 Hamilton M. Development of a rating scale for primary depressive illness. British Journal Soc Clin Psychol 1967;6(4):278-96.
43. Higgins 1994 Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badjer GJ. Incentives Improve Outcome in Outpatient Behavioral Treatment of Cocaine Dependence. Archives of General Psychiatry 1994;51(7):568- 76.
44. Higgins 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library 2006, issue 3.
45. Kampman 1998 Kampman K, Volpicelli JR, McGinnis DE, Alterman AI, Weinrieb RM, D'Angelo L, et al. Reliability and validity of the cocaine selective severity assessment. Addict Behav 1998;23(4):449-61.
46. Karch 2006 Karch SB. A Brief History of Cocaine. 2nd Edition. New York, NY: CRC Press, 2006.
47. Kay 1992 Karch SB. A Brief History of Cocaine. Vol. 2nd edition, New York NY: CRC Press, 1992.
48. Kosten 1996 Kosten T, McCance E. A review of pharmacotherapies for substance abuse. American Journal of Addiction 1996;5(1):58-65.
49. Kuhar 1996 Kuhar MJ, Pilotte NS. Neurochemical changes in cocaine withdrawal. Trends in Pharmacological Sciences 1996;17(7):260-4.
50. Leucht 1999 Leucht S, Pitschel-Waltz G, Abraham D, Kissling W. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35(1):51-68.
51. Lima 2003 Lima MS, Reisser AAP, Soares BGO, Farrell M. Antidepressants for cocaine dependence. Cochrane Database of Systematic Reviews 2003, Issue 2.Art.No.: CD002950. DOI:10.1002/14651858.CD002950.
52. Lima Reisser 2000 Lima Reisser A, Lima MS, Soares BGO, Farrell M. Carbamazepine for cocaine dependence. Cochrane Database of Systematic Reviews 2000, Issue 2.Art. No.: CD002023. DOI:10.1002/14651858.CD002023.
53. Mattick 2003 Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2003, Issue 2.Art. No.: CD002207. DOI:10.1002/14651858.CD002207.pub3.
54. McCormack 1988 Mc Cormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales. A critical review. Psychological Medicine 1988;18:1007-19.
55. McLellan 1992 McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The fifth edition of the Addiction Severity Index. Journal Substance Abuse Treatment 1992;9(3):199-213.
56. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
57. Moher 1999 Moher D, Cook DJ, Eastwood S, Olkin I, Drummond R, Stroup DF for the Quorum Group. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUORUM statement. Lancet 1999;354(9193):1896-900.
58. NSDUH 2005 Substance Abuse and Mental Health Services Administration (2005). Overview of Findings from the 2004 National Survey on Drug Use and Health (Office of Applied Studies, NSDUH Series H-27, DHHS Publication No. SMA 05-4061). Rockville, MD.
59. Ntais 2005 Ntais C, Pakos E, Panayiotis K, Ioannidis JPA. Benzodiazepines for alcohol withdrawal. Cochrane Database of Systematic Reviews 2005, Issue 3.Art. No.: CD005063. DOI:10.1002/14651858.CD005063. pub2.
60. O'Brian 2001 O'Brian C. Drug addiction and drug abuse. In: Hardman JG, Lee CL editor(s). The pharmacological basis of Therapeutics. New York: MC-Graw-Hill, 2001:621-42.
61. Polycarpou 2005 Polycarpou A, Papanikolaou P, Contopoulos- Ioannidis DG, Ioannidis JPA. Anticonvulsants for the management of alcohol withdrawal. Cochrane Database of Systematic Reviews 2005, Issue 3.
62. Schulz 1995 Schulz, KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
63. Siliquini 2005 Siliquini R, Morra A, Versino E, Renga G. Recreational drug consumers: who seek treatment?. European Journal of Public Health 2005;15(6):580-6.
64. Smelson 1999 Smelson DA, McGee-Caulfield E, Bergstein P, Engelhart C. Initial validation of the voris cocaine craving scale: a preliminary report. Journal of Clinical Psychology 1999 1999;55(1):135-9.
65. Soares 2001 Soares BGO, Lima MS, Farrell M (Protocol). Psychosocial treatments for psychostimulants dependence. Cochrane Database of Systematic Reviews 2001, Issue 3.
66. Soares 2003 Soares BGO, Lima MS, Reisser AAP, Farrell M. Dopamine agonists for cocaine dependence. Cochrane Database of Systematic Reviews 2003, Issue 2.Art. No.: CD003352. DOI:10.1002/14651858.CD003352.
67. Somoza 1995 Somoza E, Dyrenforth S, Goldsmith J, Mezinskis J, Cohen M. In search of a universal drug craving scale. Annual Meeting of the American Psychiatric Association. 1995.
68. Sorensen 1991 Sorensen JL, Wermuth LA, Gibson DR, Choi K, Guydish JR. Preventing AIDS in drug abusers and their sexual partners. New York: Guilford, 1991.
69. Suelves 2001 Suelves JM, Brugal MT, Cayla JA, Torralba L. Change in health-related problems of cocaine consumption in Catalonia, Spain. Med Clin (Barc) 2001;117(15):581-3.
70. Tiffany 1993 Tiffany ST, Singleton E, Haertzen CA, Henningfield JE. The development of a cocaine craving questionnaire. Drug and Alcohol dependence 1993;34(1):19-28.
71. Topp 2003 Topp L, Day C, Degenhardt L. Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. Drug & Alcohol Dependence 2003;70(3):275-86.
72. Volkow 2003 Volkow ND, Fowler JS, Wang GJ. The addicted human brain: Insights for imaging studies. Journal of Clinical Investigation 2003;111(10):1444-51.